SEK 0.05
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
SpectraCure AB (publ) specializes in oncology, developing innovative cancer treatments that harness laser light and photodynamic agents. A cornerstone of their research is the IDOSE software, which powers an interstitial photodynamic therapy (PDT) system. This cutting-edge system is currently in Phase II clinical trials, where its efficacy in addressing solid tumors is being evaluated. The Swedish company, established in Lund in 2003, continues to advance its therapeutic solutions.
Company Valuation
From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks.
Data is available to registered users only